BUZZ-Merck rises on license deal with China's Hansoh Pharma ** Shares of drugmaker Merck MRK.N rise 1.5% to $101.57 premarket
** MRK and Chinese biotech Hansoh Pharma 3692.HK have signed global licensing deal for experimental obesity drug, HS-10535, co says
** Hansoh to receive $112 mln upfront and $1.9 bln in milestone payments
** MRK will take $112 mln charge before taxes in Q4 2024 as part of the deal
** 21 of 28 brokerages rate the stock "buy" or higher and 7 "hold"; their median PT is $130 - LSEG
** As of last close, stock has fallen 8.2% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments